Use of reliable contraceptives and its correlates among women participating in Simulated HIV vaccine efficacy trials in key-populations in Uganda

Andrew Abaasa1,2*, Jim Todd2, Yunia Mayanja1, Matt Price3,4, Patricia E. Fast3,5, Pontiano Kaleebu1 & Stephen Nash2

To prevent pregnancy in trials, reliable contraceptive use is key. We investigated reliable contraceptive use at baseline and six months in key-populations in Uganda, during two Simulated HIV Vaccine Efficacy trials (SiVETs). SiVETs were nested within observational cohorts of Fisherfolk (2012–2014) and Female sex workers (2014–2017). Women in the observational cohorts were screened and enrolled into the SiVET. The trial administered a licensed Hepatitis B vaccine at 0, 1 and 6 months. Contraceptive use data were recorded at baseline and follow-up clinic visits. Reliable contraceptives (injectable Depot Medroxyprogesterone Acetate (DMPA), implant, pills, and intrauterine device (IUD)) were promoted and provided to women not using a reliable method at enrolment. Overall, 367 women were enrolled. At baseline 203 (55%) reported use of reliable contraceptive. Of the 164 women not using a reliable method at enrolment, 131 (80%) started using them during follow-up bringing the overall number to 334 (91%) at the end of follow-up. Young age (≤35 years) was an independent predictor of reliable contraceptive use at both time points while other factors varied. Promotion and provision of reliable contraceptives increased the proportion using them and could help reduce the risk of pregnancy in future HIV prevention trials.

Sub-Saharan Africa (SSA) suffers the highest burden of HIV with 70% of the people living with HIV in 2017 being residents in SSA1. Similarly, global estimates show that 65% of new HIV infections in 2017 happened in this region1. Some sub-populations, such as members of fishing communities (fisherfolks-FF) and female sex workers (FSW), are disproportionately affected. The HIV prevalence in fishing communities is as high as 37%2–6 and annual HIV incidence of more than 3 per 100 person years have been reported7,8. The HIV burden is worse among women2,4. Because of the high HIV incidence, these communities are attractive for the conduct of HIV vaccine efficacy trials. However, trials could take months or years from recruitment to completion. In this long period, women could become pregnant and might have to be withdrawn from follow up due to unknown effects of the new investigational product on the fetus. More withdrawals than that anticipated could have negative effects on the trial statistical power9–11. In such efficacy trials, it is important to prevent pregnancies in women participants through the use of reliable, long-acting, reversible contraceptive methods.

Reliable contraceptives defined as non-barrier methods likely to reduce the risk of pregnancy include injectable Depot medroxyprogesterone acetate (DMPA), pills, Norplant-implant and intrauterine contraceptive device (IUCD)12. The use of reliable contraceptives in women of reproductive age is low, at 64% globally, 28% in SSA and 40% in East Africa13. Lack of access to and concerns regarding side effects or health risks associated with contraceptives use have been the main reasons advanced for the low use in SSA14. In Uganda, 35% of women in the general population use reliable contraceptives, although this may be higher in specific sub-groups of the population15.

1MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda. 2London School of Hygiene and Tropical Medicine, London, UK. 3International AIDS Vaccine Initiative, New York, USA. 4University of California at San Francisco, Department of Epidemiology and Biostatistics, San Francisco, USA. 5Pediatric Infectious Diseases, School of Medicine, Stanford University, Palo Alto, California, USA. *email: Andrew.Abaasa@mrcuganda.org
Previous HIV prevention trials in non-fishing communities in Africa (East, West and Southern Africa) have shown that reliable contraceptive use is low, ranging between 5% to 28%\(^{12,16-19}\). In a 2013 review of microbicide trials in Africa the incidence of pregnancy ranged from 4.0 to 64 per 100 women-years\(^{20}\). There is little data on uptake of reliable contraception and the impact of contraception on pregnancy during these trials.

High levels of willingness (>95%) to participate in HIV vaccine efficacy trials have been shown in Africa\(^{21,22}\). However, among women this decreased to 23% when the need to prevent or delay pregnancy through use of reliable contraceptives was mentioned\(^23\). To date, no HIV vaccine efficacy trials have been conducted in women at high-risk of HIV infection in Uganda, and there is no baseline information on the use of reliable contraceptive methods to delay pregnancy during HIV prevention trials. It is unknown how the use of reliable contraceptives and risk of pregnancy would change among study participants and how this would affect HIV vaccine efficacy trials in these populations.

In populations where no baseline data on reliable contraceptives use is available, prospective trial participants may be required to use reliable contraceptive methods for at least three months before screening and enrollment\(^{24}\). This increases the cost of conducting trials and delays rollout, but avoids costly drop out from trials due to non-compliance. Studies aimed at establishing factors associated with reliable contraceptives use under efficacy trial conditions, can provide baseline data to be used in planning such trials in the FF and FSW populations where little or no information is available.

Recently, we conducted two “Simulated HIV Vaccine Efficacy Trials (SiVETs)” in which procedures and criteria for the trial mimicked an HIV vaccine efficacy trial, but the vaccine used was a licensed Hepatitis B vaccine. Participants were informed that this trial was a simulation and the vaccine would protect them against Hepatitis B, not HIV. The SiVET concept is suggested to be useful in assessing the feasibility for conduct of clinical trials of a new product, through a “simulated” trial using a commercially available vaccine\(^24,25\). This concept can inform the design and sample size estimation for the future trials\(^{26-28}\).

In this paper, we use data from the two SiVETs, in which reliable contraceptives were promoted and provided at no cost to female participants, to: determine the proportion of women using a reliable method (i) at baseline and (ii) at the end of vaccination schedule (6 months of follow up), and to determine the correlates of reliable contraceptives use (iii) at baseline and (iv) at 6 months of follow up.

### Methods

The data for this paper come from two Simulated HIV Vaccine Efficacy Trials (SiVETs) in Uganda. To assess and improve readiness for efficacy trials of HIV preventive vaccines or other investigational agents among key populations in Uganda, we conducted two trials in which licensed Hepatitis B vaccine was used in a protocol that otherwise resembled an efficacy trial for HIV vaccine. These were nested in, respectively, an observational cohort of FF (Jul 2012–Apr 2014) in Masaka and a cohort of FSW (Aug 2014–Apr 2017) in Kampala. Both studies were conducted by MRC/UVRI & LSHTM Uganda Research Unit clinics supported by the International AIDS Vaccine Initiative (IAVI). The observational cohorts details have been previously described\(^6,8,29,30\). Sexually active women were recruited by MRC/UVRI & LSHTM Uganda Research Unit clinics supported by the International AIDS Vaccine Initiative (IAVI). The observational cohorts’ quarterly follow up (aimed at determining HIV incidence) for between three and 18 months were screened for eligibility (Table 1) for enrollment into the SiVET. They were provided with a reliable contraceptive method of their choice. While DMPA and oral pills, and IUD), or unreliable (condoms, lactational amenorrhea, withdrawal etc.). The study nurse promoted reliable contraceptives to women who were not using any method, or were using an unreliable method, at baseline. Eligible women who were either already using a reliable method or were willing to initiate one were enrolled into the SiVET. They were provided with a reliable contraceptive method of their choice. While DMPA and oral pills were provided at both study site clinics (Kampala and Masaka), implant and IUD were provided by the study staff only at the Kampala clinic. At the Masaka clinic, women were referred to a Marie Stopes clinic located about one kilometre from the study research site clinic where they could obtain implant or IUD.

All enrolled women were provided with a contraceptive card, which captured the method they were using and any future changes or renewals. They were requested to carry their card every time they visited the study research clinic. Contraceptive use data was collected at enrolment, and at months one, three, and six. At enrolment, women were administered a licensed Hepatitis B vaccine (ENGERIX-BTMGlaxoSmithKline Biologicals)

| Eligible | Ineligible |
|----------|------------|
| At least 3 and no more than 18 months of follow up in the observational cohort | HIV-1 infection |
| HIV-1 negative and willing to undergo HIV testing | Pregnant or intending to get pregnant |
| Aged ≥18 years and ≤49 years | Previous exposure to Hepatitis B or current infection (only Kampala clinic) |
| Able and willing to provide informed consent | History of severe allergic reaction to any substance |
| Able and willing to provide adequate locator information | An acute or chronic illness |
| Willing and able to return for follow-up clinic visits | Contraindication for Hepatitis B vaccine |
| Intending to reside in the study area for at least one year | Participation in another clinical trial |
| Willing to undergo pregnancy testing | |
| Not breastfeeding and no intent for pregnancy in the next year | |
| Willing to use a reliable method of contraceptives during the study | |

Table 1. Eligibility Criteria for screening/enrolment into SiVET at Kampala & Masaka clinics, Uganda.
Rixensart, Belgium) following the standard schedule of 0, 1 and 6 months, akin to what might happen in an HIV vaccine efficacy trial. After each vaccination, women were retained in the clinic for at least 30 minutes for reactogenicity events assessment. Furthermore, they were requested to return after three days for further review. Details of the trial procedures and follow up have been previously described31,32.

Pregnancy testing: Women were asked to provide a urine sample at each clinic visit for pregnancy testing. A QuickVue One-Step human chorionic gonadotropin (HCG) test (manufacturer: Quidel Q20109IN) was used to determine pregnancy.

**Statistical analysis.** SIVET data were captured using OpenClinica 3.5 (Waltham, MA). The data were transferred to Stata 14 (StataCorp, College Station, TX USA) for cleaning and analysis. Variables examined included; social demographics- age, tribe, education, religion, marital status, occupation and duration of residency. Behavioral - frequency of alcohol consumption, having sex under the influence of alcohol, illicit drug use, number of sexual partners, having a new sexual partner other than the regular partner, frequency of condom use with a new sexual partner and being away from home for at least 3 days per week. Clinical – having had a genital discharge and/or genital sores/ulcer disease in the three months preceding the interview. Participant baseline socio-demographic, study site, HIV risk behavior, and clinical characteristics were summarized using counts and percentages and further stratified by study population and whether or not a participant reported use of a reliable contraceptive method at enrolment. Similarly, participant characteristics were compared between those who took up a reliable contraceptive method and those who did not. The numbers of women who took up a reliable contraceptive method overall, and at each clinic visit, were presented using a bar graph. We defined uptake of reliable contraceptives as a woman using an unreliable or no method at enrolment into SIVET but taking up one of the reliable methods at any one point during follow up. Simple logistic regression models were fitted to determine correlates of reliable contraceptives use at baseline and at the last vaccination visit (six months of follow up). After bivariable analyses, a multivariable model was fitted. In the multivariable model, factors were removed from the model using a backward elimination algorithm retaining any factors, which caused a change in the log odds of 20% or more.

**Results**

**Screening.** In total, 464 [FF = 83 and FSW = 381] sexually active women were screened for entry into the SIVETs, of whom 367 (79%; FF = 77 (93%) and FSW = 290 (76%)) non-pregnant women were enrolled, overall screening-enrolment ratio of 5:4. Of the 97 women ineligible for enrolment, the primary reason was prior exposure to Hepatitis B (54%, n = 52). Eight women (8%) were excluded because of pregnancy; other reasons for exclusion are shown in Fig. 1.

**Baseline characteristics.** In the FF population, the average age of enrolled women was 30 years (SD = 7.5, range 18–49), with 38 (49%) being of the indigenous Baganda tribe, 57 (74%) of Christian faith, 49 (64%) had primary education and 54 (70%) had lived at the current location for more than one year. All participants reported having a new sexual partner (not a regular sexual partner) in the three months preceding the interview and 47 (61%) reported never using a condom while having sex with the new sexual partner (Table 2). In the FSW population, the average age was 28 years (SD = 7.5, range 18–49), with 153 (53%) being of the indigenous Baganda tribe, 219 (76%) of Christian faith, 149 (51%) had primary education, 204 (70%) single but previously married. Two hundred and thirty nine (82%) had lived at the current location for more than one year. A total of 235 (81%) reported illicit drug use, 287 (99%) reported two or more sexual partners, 266 (92%) reported having a new sexual partner in the 3 months preceding the interview and 207 (78%) reported that they always use a condom while having sex with a new sexual partner (Table 2).

**Baseline contraceptives use (Table 2).** Of the 367 women enrolled, 213 (58%; FF = 30 (39%) and FSW = 183 (63%)) reported use of some form of contraceptive at baseline. Reliable methods were used by 203 women (55%; FF = 24 (31%) and FSW = 179 (62%)) which included 136 (67%) women using injectable DMPA, 30 (14.8%) using an implant, 29 (14%) using oral pills, 6 (3%) using an IUD and 2 (1%) women sterilized. A further 9 (3%) women used condoms and one woman (0.3%) used lactational amenorrhea. No reasons were documented for the 154 women not using contraceptives. In total, 164 women (10 using unreliable and 154 not using any method) were not using any reliable contraceptives at baseline. Adjusting for factors indicated in Table 2, age and self-reported illicit drug use were independently associated with reliable contraceptives use at baseline. Women aged 18–34 years were twice as likely to use a reliable method, adjusted odds ratio (aOR) = 2.07, 95%CI: 1.21–3.54 compared to those aged 35 years or more. Similarly, self-reported illicit drug users were twice more likely to use reliable contraceptives aOR = 2.45, 95%CI: 1.38–4.35 compared to non-illicit drug users (Table 2).

**Retention.** In total, 294 (84%) of 350 expected and 80% of 367 enrolled; FF = 64/71 (90%) and FSW = 230/279 (82%) completed all four study visits, up to six months. Overall, 23 (6%) were withdrawn from the study over the six months follow up, 11 (3%) due to pregnancy, and 12 (3%) for other reasons (see Fig. 1). Of the 11 women who became pregnant, seven (four on injectable and three on oral pills) reported using reliable contraceptive before the pregnancy while four were not using any method. The four on injectable had delayed injection by 25, 27, 35 and 40 days. Of the 367, 357 and 350 women expected at month one, three and six respectively, 94%, 87% and 84% were seen. The reasons for missing a given visit are indicated in Fig. 1. Compared to those who completed all the study follow up visits, those that missed any one visit were younger (mean age, 26.3 vs. 29.7 years), with one or no sexual partner 44 vs two or more 29%, new sexual partner 42% vs none 31%, spent up to one year at the current location 41% vs more than one year 29%.
Uptake of reliable contraceptives. The trial promoted reliable contraceptive methods to the 164 women (FF = 53 and FSW = 111) not using a reliable method at baseline; of these women 131 (80%; FF = 39 (74%) and FSW = 92 (83%)) reported using a reliable contraceptive method during at least one follow up visit. Figure 2 shows the number of women that used reliable contraceptives at each of the follow up visits, throughout the trial. The graph illustrates that 125 (76%) women started using reliable contraceptive in the first month of follow-up and 80% used reliable contraceptives at month 6. Overall, 73 (45%) of 164 women used DMPA, and 36 (22%) oral pills.

In the 164 women that were eligible for promotion of reliable contraceptives at baseline, age group and reporting having sex under the influence of alcohol in the month preceding the interview were independently associated with uptake of reliable contraceptives by six months of follow up (in a model adjusted for factors in Table 3). Women aged 18–34 years were twice more likely to take up a reliable method, adjusted odds ratio (aOR) = 2.47, 95%CI: 1.01–6.07 compared to those aged 35 years or more. Those reporting sometimes having sex under influence of alcohol were less likely to take up a reliable method compared to never (aOR = 0.37, 95%CI: 0.14–0.96, Table 3). Though not statistically significant, in this sample, women who had attained some formal education were three times (aOR = 3.21, 95%CI: 0.73–14.16) for primary education and four times (aOR = 4.41, 95%CI: 0.89–21.87) for secondary education more likely to take up a reliable method compared to those without any formal education.

Furthermore, 334 (91%; FF = 63/77 (82%) and FSW = 271/290 (93%)) of 367 women enrolled (including the 203 that were already using a reliable method of contraception at baseline) used a reliable method by the end of trial follow up. Of the 334 women that used a reliable method, 197 (59%) used DMPA. Other methods were oral pills (n = 60; 18%), implant (n = 31; 9%), IUD (n = 7; 2%), and sterilized (n = 2; 0.6%). Thirty-seven women (11%) switched between reliable methods. Of these women, most 19 (51%) switched from DMPA to oral pills. All women (131 new reliable contraceptives users and 203 already using at baseline) reported sustained use of a reliable method throughout the follow up period. Less than one tenth of women (n = 33; 9%; FF = 14 and FSW = 19) did not use any reliable method throughout the study. Of these, seven (FF = 6 and FSW = 1) used condoms and 26 (FF = 8 and FSW = 18) did not use any form of contraception.

In the 367 women enrolled in the trial, overall factors independently associated with use of reliable contraceptives by six month of follow up included; age group, with women aged 18–34 years being thrice more likely to use a reliable method of contraceptives (aOR = 2.86, 95%CI: 1.31–6.24) compared to those aged 35 or more years. Other factors included study site [Kampala, aOR = 3.09, 95%CI: 1.36–6.98] compared to Masaka] and education (borderline) [secondary or more, aOR = 3.06, 95%CI: 0.78–12.02] compared to no education.

Discussion
We investigated in women of reproductive age in the FF and FSW use of reliable contraceptive methods and associated factors at baseline and at the end of a six-month vaccination schedule in two SiVETs. We found that the proportion of sexually active women using a reliable method at baseline was low, about one in every two women. Promotion and provision of reliable methods by the trial staff increased the proportion of women using a reliable method to over 90% at the end of six months of follow up. The baseline use of reliable methods in these populations was higher than the 35% reported in the general population in Uganda. It was also higher than 5%-28% reported in other HIV prevention trials in West Africa and East Africa and Southern Africa. Contrary to
| Participant characteristic | FF n (%) | FSW n (%) | Contraceptive use FF | FSW | tOR (95%CI) | LRT-pvalue | aOR (95%CI) |
|----------------------------|----------|-----------|----------------------|-----|-------------|------------|-------------|
| Overall                    | 77 (100) | 290 (100) | 24 (31.2)            | 179 (61.7) | <0.001     | 1.56 (0.66–3.69) |
| Site                       |          |           |                      |     |             |            |             |
| Masaka                     | 77 (100) | na            | 24 (31.2)            | na   | 1.00        | 1.00       |
| Kampala                    | na        | 290 (100)       | 179 (61.7)           | 3.56 (2.08–6.09) | 0.001     |
| Age group (years)          |          |           |                      |     |             |            |             |
| 35+                        | 21 (27.3) | 62 (21.4)     | 28 (45.2)            | 1.00 | 1.00        | 2.07 (1.21–3.54) |
| 18–34                      | 56 (72.7) | 228 (78.6)    | 151 (66.2)           | 2.26 (1.37–3.72) | 0.107     |
| Tribe                      |          |           |                      |     |             |            |             |
| Maganda                    | 38 (49.3) | 153 (52.8)   | 98 (64.1)            | 1.00 |            |            |
| Manyankole                 | 7 (9.1)  | 32 (11.0)     | 19 (59.4)            | 0.86 (0.43–1.72) | 0.183     |
| Munyarwanda                | 18 (23.4) | 20 (6.9)     | 10 (50.0)            | 0.43 (0.21–0.88) | 0.685     |
| Other                      | 14 (18.2) | 85 (29.3)    | 52 (61.2)            | 1.04 (0.64–1.70) | 0.319     |
| Education                  |          |           |                      |     |             |            |             |
| None                       | 7 (9.1)  | 16 (5.5)     | 3 (42.9)             | 1.0  | 1.00        |             |
| Primary                    | 49 (63.6) | 149 (51.4)  | 87 (58.4)            | 0.80 (0.34–1.91) | 0.81 (0.32–2.05) |
| Secondary+                 | 21 (27.3) | 125 (43.1)  | 82 (65.6)            | 1.20 (0.49–2.92) | 1.00 (0.38–2.61) |
| Religion                   |          |           |                      |     |             |            |             |
| Christian                  | 57 (74.0) | 219 (75.5)  | 131 (59.8)           | 1.00 |            |            |
| Muslim                     | 20 (26.0) | 71 (24.5)    | 48 (67.6)            | 1.10 (0.68–1.78) |            |
| Marital status             |          |           |                      |     |             |            |             |
| Single, never married      | 15 (19.5) | 68 (23.5)   | 38 (55.9)            | 1.00 |            |            |
| Married                    | 30 (39.0) | 18 (6.2)     | 11 (61.1)            | 0.71 (0.35–1.46) |            |
| Single, previously married| 32 (41.5) | 204 (70.3)  | 130 (63.7)           | 1.15 (0.77–1.82) |            |
| Occupation                 |          |           |                      |     |             |            |             |
| Fishing/related            | 21 (27.3) | 0 (0.0)     | 0 (0.0)              | 1.00 |            |            |
| Small scale business       | 27 (35.1) | 11 (3.8)    | 9 (81.8)             | 2.09 (0.63–6.90) |            |
| Hotel/Bar/Saloon           | 19 (24.6) | 111 (38.3)  | 67 (60.4)            | 4.65 (1.61–13.46) |            |
| Sex work                   | 0 (0.0)  | 165 (56.9)   | 101 (61.2)           | 5.05 (1.76–14.46) |            |
| Other                      | 10 (13.0) | 3 (1.0)     | 2 (66.7)             | 2.00 (0.45–8.98) |            |
| Duration lived at current location | | | | | 0.614 |
| 0–1, year                  | 23 (29.9) | 51 (15.6)   | 31 (60.8)            | 1.00 |            |            |
| >one year                  | 54 (70.1) | 239 (82.4)  | 148 (61.9)           | 1.14 (0.68–1.90) |            |
| Alcohol consumption (previous one month) | | | | | 0.099 |
| None                       | 33 (42.9) | 57 (19.7)   | 30 (52.6)            | 1.00 |            |            |
| Inconsistent               | 38 (49.3) | 147 (50.6)  | 98 (66.7)            | 1.71 (1.03–2.85) |            |
| Daily                      | 6 (7.8)  | 86 (29.7)   | 51 (59.3)            | 1.62 (0.90–2.92) |            |
| Sex under alcohol influence (previous one month) | | | | | 0.222 |
| Never                      | 45 (58.4) | 103 (35.5)  | 63 (61.2)            | 1.00 |            |            |
| Sometimes                  | 24 (31.2) | 169 (58.3)  | 105 (62.1)           | 1.44 (0.93–2.21) |            |
| Frequently                 | 8 (10.4) | 18 (6.2)    | 11 (61.1)            | 0.97 (0.42–2.24) |            |
| Drug use (previous one month) | | | | | <0.001 |
| No                         | 71 (92.2) | 55 (19.0)   | 24 (43.6)            | 1.00 | 1.00        |            |
| Yes                        | 6 (7.8)  | 235 (81.0)  | 155 (66.0)           | 3.43 (2.18–5.38) | 2.45 (1.38–4.35) |
| Genital discharge (previous 3 months) | | | | | 0.055 |
| Yes                        | 51 (55.2) | 88 (30.3)   | 54 (61.4)            | 1.00 |            |            |
| No                         | 26 (33.8) | 202 (69.7)  | 125 (61.9)           | 1.52 (0.99–2.31) |            |
| Genital sores/ulcer disease (previous 3 months) | | | | | 0.009 |
| Yes                        | 40 (52.0) | 48 (16.6)   | 27 (56.3)            | 1.00 |            |            |
| No                         | 37 (48.0) | 242 (83.4)  | 152 (62.8)           | 1.90 (1.17–3.09) |            |
| Number of sexual partners (previous 3 months) | | | | | <0.001 |
| 0/1                        | 47 (61.0) | 3 (1.0)     | 2 (66.7)             | 1.00 | 1.00        |            |
| 2+                         | 30 (39.0) | 287 (99.0)  | 177 (61.7)           | 3.40 (1.78–6.48) | 1.30 (0.52–3.29) |
| New sexual partner (previous 3 months) | | | | | 0.758 |
| No                         | 0 (0.0)  | 24 (8.3)    | 14 (58.3)            | 1.00 |            |            |
| Yes                        | 77 (100) | 266 (91.7)  | 165 (62.0)           | 0.88 (0.38–2.03) |            |
| Continued                  | | | | | |
these HIV prevention trials, women enrolled into SiVET were selected based on willingness to delay pregnancy through use of a reliable method of contraceptive during the vaccination period. In SiVET, the majority of women reporting reliable contraceptive use at baseline and at the end of vaccination used injectable DMPA, which is consistent with both national data and data from concluded HIV prevention trials in Uganda.

At baseline, reliable contraceptive use differed significantly by age group and self-reported illicit drug use. Nationally age has been associated with contraceptive use. This is also consistent with previous studies in East and Southern Africa that reported association of effective contraceptives use with age. Contrary to previous studies that showed high contraceptives use among non-drug users, we found a twofold higher use of reliable contraceptives among illicit drug users. Women involved in sex work dominated the SiVET protocol and these have been linked to high illicit drug and contraceptives use. It is likely that the perceived risk of pregnancy in this category of women is higher than that of the general population and could influence practices.

About half of the women were not using reliable contraceptive methods at baseline but majority started using them mainly within the first month of follow up. By six months, nine in every ten women were using a reliable method of contraceptives. Uptake of reliable contraceptives in women that were not using such methods at baseline was independently associated with age group, education (borderline) and self-reported having had sex under alcohol influence. Similarly, older age and lower educational status are associated with lower contraceptive use nationally. Women that reported sometimes or frequently having sex under influence of alcohol were less likely to use reliable contraceptives. Alcohol use has been linked to impaired decision making in complex situations.

Though women switched between contraceptive methods, it was encouraging that the switches were within reliable methods and women sustained use of these methods throughout follow up. Uptake and sustained use coupled with higher baseline use of reliable methods than that in the general population could have played a role in the relatively lower proportion of pregnancy than that observed in other HIV prevention trials. Seven women got pregnant while using reliable contraceptives in the trial. The four women on injectable DMPA had all delayed an injection by about one month perhaps indicating they were unaware of the need to renew on time. Three women were using oral pills and adherence issues with use of oral pills have been well-documented. In an actual HIV vaccine efficacy trial, these women would have to be withdrawn from the trial. Encouraging women

| Participant characteristic | FF n (%) | FSW n (%) | Contraceptive use | uOR (95%CI) | LRT-pvalue | aOR (95%CI) |
|---------------------------|----------|-----------|-------------------|-------------|------------|-------------|
| Condom use with the new sexual partner |           |           |                   |             |            |             |
| Never                     | 47 (61.0) | 9 (3.4)   | 15 (31.9)         | 6 (66.7)    | 1.00       |             |
| Sometimes                 | 19 (24.7) | 50 (18.8) | 6 (31.6)          | 26 (52.0)   | 1.44 (0.70–2.96) |  |
| Always                    | 11 (14.3) | 207 (77.8)| 3 (27.3)          | 133 (64.3)  | 2.76 (1.51–5.07) |  |
| Away from home ≥ 3 days/week |         |           |                   |             | 0.741      |             |
| Yes                       | 24 (31.2) | 98 (33.8) | 6 (25.0)          | 60 (61.2)   | 1.00       |             |
| No                        | 53 (68.8) | 192 (66.2)| 18 (34.0)         | 119 (62.0)  | 1.08 (0.70–1.67) |  |

Table 2. Participant baseline characteristics, proportion and factors associated with using reliable contraceptives among 367 participants enrolled in SiVET in Uganda (2012–2017). uOR-Unadjusted odds ratio, aOR-Adjusted odds ratio, CI-Confidence interval, %—percent, na-Not applicable, LRT = likelihood ratio test. FF-Fisherfolk, FSW-Female sex workers.
| Participant characteristic | FF n (%) | Uptake | FSW n(%) | uOR (95%CI) | LRT p-value | aOR (95%CI) |
|-----------------------------|----------|--------|----------|------------|-------------|-------------|
| FF                         | 111 (100)| 39 (73.6)| 92 (82.9) | na         | na          | na          |
| Masaka                     | 33 (100) | na     | 39 (73.6) | 1.00       | 0.172       | 1.00        |
| Kampala                    | 111 (100)| na     | 92 (82.9) | 1.74 (0.79–3.81) | 1.37 (0.50–3.73) |
| Age group (years)          |          |        |          |            |             |             |
| 35+                        | 16 (30.2)| 34 (50.6) | 8 (50.0) | 1.00       | 0.041       | 1.00        |
| 18–34                      | 37 (69.8)| 77 (69.4) | 31 (83.8) | 65 (84.4) | 2.29 (1.04–5.02) | 2.47 (1.01–6.07) |
| Tribe                      |          |        |          |            |             |             |
| Muganda                    | 26 (49.1)| 55 (49.6) | 22 (84.6) | 44 (80.0) | 1.00       | 0.120       |
| Munyankole                 | 5 (9.4)  | 13 (11.7) | 3 (60.0) | 11 (84.6) | 0.88 (0.23–2.76) |          |
| Munyarwanda                | 14 (26.4)| 10 (9.0) | 7 (70.0) | 8 (80.0) | 0.38 (0.14–1.03) |          |
| Other                      | 8 (15.1) | 33 (29.7) | 7 (87.5) | 29 (87.9) | 1.64 (0.55–4.87) |          |
| Education                  |          |        |          |            |             |             |
| None                       | 4 (7.6)  | 6 (5.4) | 2 (50.0) | 4 (66.7) | 1.00       | 0.086       | 1.00        |
| Primary                    | 35 (66.0)| 62 (55.9) | 25 (71.4) | 50 (80.7) | 2.27 (0.59–8.78) | 3.21 (0.73–14.16) |
| Secondary+                 | 14 (26.4)| 43 (38.7) | 12 (85.7) | 38 (88.4) | 4.76 (1.07–21.17) | 4.41 (0.89–21.87) |
| Religion                   |          |        |          |            |             |             |
| Christian                  | 37 (69.8)| 88 (79.3) | 27 (73.0) | 73 (83.0) | 1.00       | 0.945       |          |
| Muslim                     | 16 (30.2)| 23 (20.7) | 12 (75.0) | 19 (82.6) | 0.97 (0.40–2.36) |          |
| Marital status             |          |        |          |            |             |             |
| Single never married       | 8 (15.1) | 30 (27.0) | 7 (87.5) | 25 (83.3) | 1.00       | 0.156       | 1.00        |
| Married                    | 19 (35.8)| 7 (6.3) | 12 (63.2) | 5 (71.4) | 0.35 (0.11–1.16) | 0.39 (0.10–1.62) |
| Single ever married        | 26 (49.1)| 74 (66.7) | 20 (76.9) | 62 (83.8) | 0.85 (0.31–2.35) | 1.08 (0.35–3.39) |
| Occupation                 |          |        |          |            |             |             |
| Fishing/related            | 16 (30.2)| 0 (0.0) | 11 (68.8) | 0 (0.0) | 1.00       | 0.223       |
| Small scale business       | 21 (39.6)| 2 (1.8) | 17 (81.0) | 2 (100) | 2.16 (0.48–9.77) |          |
| Hotel/Bar/Saloon           | 9 (17.0) | 44 (39.6) | 7 (77.8) | 33 (75.0) | 1.40 (0.41–4.78) |          |
| Sex work                   | 0 (0.0)  | 64 (57.7) | 0 (0.0) | 56 (87.5) | 3.18 (0.88–11.57) |          |
| Other                      | 7 (13.2) | 1 (0.9) | 4 (57.1) | 1 (100) | 0.76 (0.13–4.49) |          |
| Duration lived at current location | | | | | | |
| 0–1, year                  | 15 (28.3)| 20 (18.0) | 13 (86.7) | 15 (75) | 1.00       | 0.984       |
| > one year                 | 38 (71.7)| 91 (82.0) | 26 (68.4) | 77 (84.6) | 0.99 (0.39–2.52) |          |
| Alcohol consumption (previous one month) | | | | | | |
| Non                       | 22 (41.5)| 27 (24.3) | 17 (77.3) | 23 (85.2) | 1.00       | 0.173       |
| Inconsistent              | 27 (50.9)| 49 (44.1) | 21 (77.8) | 43 (87.8) | 1.20 (0.46–3.10) |          |
| Daily                     | 4 (7.6)  | 35 (31.6) | 1 (25.0) | 26 (74.3) | 0.51 (0.19–1.37) |          |
| Sex under alcohol influence (previous one month) | | | | | | |
| Never                    | 33 (62.3)| 40 (36.0) | 26 (78.8) | 36 (90.0) | 1.00       | 0.343       | 1.00        |
| Sometimes                | 14 (26.4)| 64 (57.7) | 10 (71.4) | 49 (76.6) | 0.55 (0.24–1.26) | 0.37 (0.14–0.96) |
| Frequently               | 8 (15.1) | 7 (6.3) | 3 (50.0) | 7 (100) | 0.59 (0.14–2.50) | 0.70 (0.15–3.34) |
| Drug use (previous one month) | | | | | | |
| No                       | 50 (94.3)| 31 (27.9) | 36 (72.0) | 26 (83.9) | 1.00       | 0.292       |
| Yes                      | 3 (5.7)  | 80 (72.1) | 3 (100) | 66 (82.5) | 1.51 (0.70–3.26) |          |
| Genital discharge (previous 3 months) | | | | | | |
| Yes                      | 37 (69.8)| 34 (30.6) | 27 (73.0) | 26 (76.5) | 1.00       | 0.146       |
| No                       | 16 (30.2)| 77 (69.4) | 12 (75.0) | 66 (85.7) | 1.77 (0.82–3.81) |          |
| Genital sores/ulcer disease (previous 3 months) | | | | | | |
| Yes                      | 29 (54.7)| 21 (18.9) | 21 (72.4) | 15 (71.4) | 1.00       | 0.103       | 1.00        |
| No                       | 24 (45.3)| 90 (81.1) | 18 (75.0) | 77 (85.6) | 1.94 (0.88–4.28) | 1.92 (0.78–4.73) |
| Number of sexual partners (previous 3 months) | | | | | | |
| 0/1                      | 34 (64.2)| 1 (0.9) | 26 (76.5) | 1 (100) | 1.00       | 0.653       |
| 2+                       | 19 (35.8)| 110 (99.1) | 13 (68.4) | 91 (82.7) | 1.23 (0.50–3.04) |          |
| New sexual partner (previous 3 months) | | | | | | |
| No                       | 0 (0.0)  | 10 (9.0) | 0 (0.0) | 9 (90.0) | 1.00       | 0.374       |
| Continued                | | | | | | |
to receive their contraception injection or take their pills on time through phone calls and/or home visits would improve adherence.

The retention in SiVET was higher than the average (75%) reported in observational cohorts\(^7,29,30\) in these populations. High retention in the trial setting is likely a result of the rigorous participant tracking system employed compared to observational cohorts. Though it took about three months for 5% of the new reliable contraceptive users to get on reliable contraceptives, most had done so within a month of enrolment. In these key populations, it may not be necessary to put women on reliable contraceptives for at least three months before screening for trial enrolment instead these could happen concurrently. The high retention coupled with high screening-enrolment ratio and high use of reliable contraceptives make women in these key populations attractive to enroll in the future HIV vaccine efficacy and other HIV prevention trials.

A limitation of our trial is that we did not collect data on the reasons for not using reliable or any contraceptives. Furthermore, we did not collect data on reasons for switching between reliable methods. Such reasons would have been instrumental in informing modification of messages on contraceptives use in HIV prevention trials in these key populations. Even though the trials (in FF and FSW) were similar, two different study teams with a somewhat different protocol conducted them. Differences in correlates of reliable contraceptive use may exist by site, but the small sample size prevented site stratification. However, other than occupation and illicit drug use, most of the women characteristics in the two populations were comparable.

The major strength of our trial is that we promoted and provided reliable contraceptives in the context of HIV vaccine efficacy trial, counselled women on the importance of reliable contraceptives use and provided them with a method of their choice.

**Conclusion**

In this SiVET, the proportion of women using reliable contraceptives improved from one in every two women at baseline to nine in every 10 women at the end of follow up. The use of reliable methods at baseline was particularly higher among young women and illicit drug users. Promotion and provision of reliable contraceptives to women not using them at baseline improved the proportion using them within the first month of follow up. Uptake of reliable contraceptives increased with increasing education and decreased with increasing age and the frequency of having sex under alcohol influence. All women using reliable methods continued to use them (or another reliable method) throughout follow up. The sustained use highlights the importance of promoting and providing reliable contraceptives to trial participants in populations where pregnancy could lead to discontinuation of the use of investigational product. We observed a lower proportion of women becoming pregnant during the trial follow up than that reported in the concluded HIV prevention trials in the region. This trial could have filled the unmet need for reliable contraceptives in these populations in term of promotion and provision as well as enhancing accurate contraceptive messaging. It is particularly encouraging that concurrent vaccination and provision of contraceptives was possible in these populations making them good candidates for future HIV vaccine efficacy and other prevention trials.

**Declarations**

**Ethics approval and consent to participate.** The Uganda Virus Research Institute (UVRI) Research and Ethics Committee (GC/127/12/04/22 and GC127/12/06/01) and the Uganda National Council for Science and Technology (HS364 and HS1584) approved the conduct of the SiVET protocols. The London School of Hygiene and Tropical Medicine Observational/Interventions Research Ethics Committee (LSHTM14588) approved the concept leading to this analysis. Written informed consent/assent was obtained for each participant before enrolment.

**Study methods confirmation.** We confirm that all methods in this manuscript were performed in accordance with the relevant guidelines and regulations.

| Participant characteristic | FF n (%) | Uptake | FSW n (%) | aOR (95%CI) | LRT p-value | aOR (95%CI) |
|---------------------------|----------|--------|-----------|-------------|-------------|-------------|
| Condom use with the new sexual partner | | | | | | |
| Never | 32 (60.4) | 3 (3.0) | 24 (75.0) | 3 (100) | 1.00 | 0.721 |
| Inconsistently | 13 (24.5) | 24 (23.7) | 9 (69.2) | 22 (91.7) | 1.53 (0.47–5.00) |
| Always | 8 (15.1) | 74 (73.3) | 6 (75.0) | 58 (78.4) | 1.00 (0.39–2.56) |
| Away from home ≥3 days/week | | | | | | |
| Yes | 18 (34.0) | 38 (34.2) | 16 (88.9) | 29 (76.3) | 1.00 | 0.912 |
| No | 35 (66.0) | 73 (65.8) | 23 (65.7) | 63 (86.3) | 0.96 (0.43–2.15) |

Table 3. Proportion and factors associated with uptake of reliable contraceptives among 164 women that were not using reliable methods at enrolled into SiVET in Uganda (2012–2017). uOR-Unadjusted odds ratio, aOR-Adjusted odds ratio, CI-Confidence interval, %-percent, na-Not applicable, FF-Fisherfolk, FSW-Female sex workers.
References

1. UNAIDS. State of the epidemic (2018).
2. Mafigiri, R. et al. HIV prevalence and uptake of HIV/AIDS services among youths (15–24 Years) in fishing and neighboring communities of Kasensero, Rakat District, South Western Uganda. BMC public health 17, 251 (2017).
3. Opio, A., Muyonga, M. & Mulumba, N. HIV infection in fishing communities of Lake Victoria Basin of Uganda—a cross-sectional sero-behavioral survey. PloS one 8, e70770 (2013).
4. Asiki, G. et al. HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda. Sexually transmitted infections, sti. 2010, 046805 (2011).
5. Hladik, W. et al. Burden and characteristics of HIV infection among female sex workers in Kampala, Uganda—a respondent-driven sampling survey. BMC public health 17, 565 (2017).
6. Vandaepatte, J. et al. HIV and other sexually transmitted infections in a cohort of women involved in high risk sexual behaviour in Kampala, Uganda. Sexually transmitted diseases 38, 316 (2011).
7. Kiwanuka, N. et al. An assessment of fishing communities around Lake Victoria, Uganda, as potential populations for future HIV vaccine efficacy studies: an observational cohort study. BMC public health 14, 986 (2014).
8. Seelye, J. et al. High HIV incidence and socio-behavioral risk patterns in fishing communities on the shores of Lake Victoria, Uganda. Sexually transmitted diseases 39, 433–439 (2012).
9. Raymond, E. et al. Pregnancy in effectiveness trials of HIV prevention agents. Sexually transmitted diseases 34, 1035–1039 (2007).
10. Odotula, A. et al. Pregnancy and contraceptive use among women participating in an HIV prevention trial in Tanzania. Sex Transm Infect, sextrans-2011-050412 (2012).
11. Callahan, R. et al. Pregnancy and contraceptive use among women participating in the FEM-PrEP trial. JAIDS Journal of Acquired Immune Deficiency Syndromes 68, 196–203 (2015).
12. Abasa, A. et al. Uptake of hormonal contraceptives and correlates of uptake in a phase III clinical trial in rural South Western Uganda. Reproductive health 14, 36 (2017).
13. UNESCO. Trends in Contraceptive Use Worldwide (2015).
14. Sedgh, G. & Hussain, R. Reasons for contraceptive nonuse among women having unmet need for contraception in developing countries. Studies in family planning 45, 151–169 (2014).
15. UBOS. Uganda Demographic and Health Survey (2016).
16. Peterson, L. et al. SAVVY®(C31G) gel for prevention of HIV infection in women: A phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PloS one 2, e1512 (2007).
17. Feldthun, P. et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PloS one 3, e13474 (2008).
18. Nguere, K. et al. Contraceptive method and pregnancy incidence among African women in HIV-1 serodiscordant partnerships. AIDS (London, England) 26, 513 (2012).
19. Murnane, P. et al. Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception. AIDS (London, England) 28, 1825 (2014).
20. Musekwa, A., Machiri, E., Manda, S. O. & Mwambi, H. G. Pregnancy incidence and risk factors among women participating in vaginal microbicide trials for HIV prevention: systematic review and meta-analysis. PloS one 8, e77041 (2013).
21. Ruzagira, E. et al. Willingness to participate in preventive HIV vaccine trials in a community-based cohort in south western Uganda. Tropical medicine & international health 14, 196–203 (2009).
22. Asiki, G. et al. Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda. Vaccine 31, 5053–5061 (2013).
23. Kusemererwa, S. et al. Contraceptive preference among women at risk of HIV acquisition in a preparatory screening study for a phase III microbicide trial in south western Uganda. AIDS and Behavior, 1–8 (2018).
24. Susan., A. A Simulated Vaccine Efficacy Trial Using MMR and Tdap-IPV Vaccines in Healthy, HIV Negative Women at High Risk of HIV Infection in Lusaka and Ndola, Zambia. clinical-trials-registry/NCT02589678 (2017).
25. Wallace, M. et al. Feasibility and acceptability of conducting HIV vaccine trials in adolescents in South Africa: Going beyond willingness to participate towards implementation. South African Medical Journal 108, 291–298 (2018).
26. Hitchings, M. D. T., Grais, R. F. & Lipsitch, M. Using simulation to aid trial design: Ring-vaccination trials. PLoS neglected tropical diseases 11, e005470 (2017).
27. Benoit, A., Legrand, C. & Dewé, W. Influenza vaccine efficacy trials: a simulation approach to understand failures from the past. Pharmaceutical statistics 14, 294–301 (2013).
28. Cuadros, D. F., Abu-Raddad, L. J., Awad, S. F. & García-Ramos, G. Use of agent-based simulations to design and interpret HIV clinical trials. Computers in biology and medicine 50, 1–8 (2014).
29. Bahemuka, U. M. et al. Retention of adults from fishing communities in an HIV vaccine preparedness study in Masaka, Uganda. bioRxiv, 365148 (2018).
30. Abasa, A. et al. Factors associated with dropout in a long term observational cohort of fishing communities around lake Victoria, Uganda. BMC research notes 8, 815 (2015).
31. Abasa, A. et al. Comparison of HIV incidence estimated in clinical trial and observational cohort settings in a high risk fishing population in Uganda: Implications for sample size estimates. Vaccine 34, 1778–1785 (2016).
32. Asiki, G. et al. Participation of Individuals from Fishing Communities in a Simulated Vaccine Efficacy Trial in Preparation for Future HIV Prevention Work. AIDS research and human retroviruses 30, A163–A163 (2014).
33. Terplan, M., Hand, D. J., Hutchinson, M., Salisbury-Afsahr, E. & Heil, S. H. Contraceptive use and method choice among women with opioid and other substance use disorders: a systematic review. Preventive medicine 80, 23–31 (2015).
34. Cornford, C. S., Close, H. J., Bray, R., Beere, D. & Mason, J. M. Contraceptive use and pregnancy outcomes among opioid drug-using women: a retrospective cohort study. PLoS One 10, e0116231 (2015).
35. Medhi, G. K. et al. Factors associated with history of drug use among female sex workers (FSW) in a high HIV prevalence state of India. *BMC public health* **12**, 273 (2012).

36. Martin, C. E. et al. Contraceptive use among female sex workers in three Russian cities. *International Journal of Gynecology & Obstetrics* **131**, 156–160 (2015).

37. Brevers, D. et al. Impaired decision-making under risk in individuals with alcohol dependence. *Alcoholism: clinical and experimental research* **38**, 1924–1931 (2014).

**Acknowledgements**

We would like to acknowledge the study participants, the investigators and study team. SiVET protocols were mainly funded by IAVI with some support from the UK Medical Research Council. IAVI receives the generous support of USAID and other donors; a full list of IAVI donors is available at www.iavi.org. The contents of this manuscript are the responsibility of IAVI and co-authors and do not necessarily reflect the views of USAID or the US Government. For this manuscript, the funders had no role in data analysis and its interpretation.

**Author contributions**

A.A. Lead Author, drafted initial manuscript draft, carried out data management for SiVET, data analysis and interpreted the data. J.T. contributed to data analysis and interpreted the data. Y.M. contributed to the design of the SiVET protocol and study coordination. M.P. contributed to the design of the SiVET protocol and interpreted the data. P.E.F. contributed to the design of the SiVET protocol and interpreted the data. P.K. directed the implementation of the SiVET protocol and S.N. contributed to data analysis and interpreted the data. All authors critically commented and provided revisions to the manuscript. The authors approved this final version for submission.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Correspondence and requests for materials should be addressed to A.A.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019